英国卫生部批准将Lecanemab(一种潜在的阿尔茨海默氏病药物)用于私人处方; NICE决定推出国民保健制度。 UK's MHRA approves Lecanemab, a potential Alzheimer's drug, for private prescription use; NICE to decide on NHS rollout.

阿尔茨海默氏病的药物Lecanemab可能使认知下降减缓27%,该药物将由医药和保健产品管理局批准在联合王国私人处方使用。 Alzheimer's drug Lecanemab, which may slow cognitive decline by 27%, is set to be approved for private prescription use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). 国家卫生和护理卓越研究所 (NICE) 将确定该药是否适合NHS推出. The National Institute for Health and Care Excellence (NICE) will determine if the drug is suitable for NHS rollout. Lecanemab是一种单克隆抗体药物,已经获准在美国使用,目的是从大脑中清除有毒的氨基类蛋白。 Lecanemab, a monoclonal antibody medication, has already been approved for use in the US and aims to clear toxic amyloid proteins from the brain. 然而,欧洲医药局拒绝使用该药物,因为担心会产生诸如肿胀和潜在脑出血等副作用。 However, the European Medicine Agency rejected the drug due to concerns about side effects like swelling and potential brain bleeds.